<DOC>
	<DOC>NCT00002135</DOC>
	<brief_summary>To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.</brief_summary>
	<brief_title>An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access</brief_title>
	<detailed_description>Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Patients must have: AIDS. Stable CMV retinitis. Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days. No permanent central IV catheter at present. Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis. Consent of guardian if less than legal age of consent. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Require continuation of concomitant medications precluded by this protocol. Concurrent Medication: Excluded: Intravitreal antiCMV treatment. Any other concomitant medications precluded by the protocol. Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir or ganciclovir.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1995</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Administration, Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>